Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Selling Consumer Division To Unilever Could Give ‘New GSK’ A Lift

Funds Could Aid ‘New GSK’ Rejuvenation

Executive Summary

Activist investors last year called for GSK to find an outright buyer for the consumer division, and may now get their wish.

You may also be interested in...



Q4 Earnings Preview: It's All About Growth Goals And Deal Plans (Part 2)

Industry's big players report fourth quarter results over the next two weeks. Updates on leadership changes, growth targets and deal plans are among the hot topics.

J.P. Morgan Day 2: What's Next For Pharma, From Alzheimer's To Omicron

Daily notebook from the virtual J.P. Morgan Healthcare Conference: Alzheimer's rivals Roche and Lilly address their attempts at a different launch for their anti-amyloid therapies than Biogen's Aduhelm. GSK is buoyed by sotrovimab's efficacy against Omicron, BioNTech looks to the future of mRNA and Sanofi, Amgen and AbbVie defend their growth strategies. 

Another Activist Investor Joins Calls For GSK Leadership Review

A second activist investor has called for GSK to consider replacing Emma Walmsley as CEO, and has underlined competitive threats to a key pipeline candidate.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC145720

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel